Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.

Bieńkowski M, Piaskowski S, Stoczyńska-Fidelus E, Szybka M, Banaszczyk M, Witusik-Perkowska M, Jesień-Lewandowicz E, Jaskólski DJ, Radomiak-Załuska A, Jesionek-Kupnicka D, Sikorska B, Papierz W, Rieske P, Liberski PP.

PLoS One. 2013 Jun 6;8(6):e65444. doi: 10.1371/journal.pone.0065444. Print 2013.

2.

Age-dependent prognostic effects of genetic alterations in glioblastoma.

Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33.

3.

Genetic analyses for predictors of radiation response in glioblastoma.

Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):704-10. Epub 2005 Jun 22.

PMID:
15978739
4.

Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.

Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B.

J Neurooncol. 2016 May;127(3):483-92. doi: 10.1007/s11060-016-2066-4. Epub 2016 Feb 2.

5.

Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.

Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, Benito R, Roldan P, Piquer J, Llacer J, Barbera J.

Clin Neuropathol. 2005 Sep-Oct;24(5):209-18.

PMID:
16167544
6.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

PMID:
19805672
7.

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.

Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M.

Neurology. 2014 Sep 23;83(13):1200-6. doi: 10.1212/WNL.0000000000000814. Epub 2014 Aug 22.

PMID:
25150284
8.

Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.

Chen JR, Xu HZ, Yao Y, Qin ZY.

Acta Neurol Scand. 2015 Nov;132(5):310-22. doi: 10.1111/ane.12401. Epub 2015 Apr 7.

PMID:
25846813
9.

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B.

Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29.

PMID:
22752145
10.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

11.

Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.

Nakano T, Yamamoto H, Nakashima T, Nishijima T, Satoh M, Hatanaka Y, Shiratsuchi H, Yasumatsu R, Toh S, Komune S, Oda Y.

Hum Pathol. 2016 Apr;50:51-61. doi: 10.1016/j.humpath.2015.11.001. Epub 2015 Nov 17.

PMID:
26997438
12.

Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.

Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, Horbinski C.

Am J Surg Pathol. 2012 Aug;36(8):1186-93. doi: 10.1097/PAS.0b013e3182518e12.

13.

Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.

Quan AL, Barnett GH, Lee SY, Vogelbaum MA, Toms SA, Staugaitis SM, Prayson RA, Peereboom DM, Stevens GH, Cohen BH, Suh JH.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703. Epub 2005 Jun 2.

PMID:
15936158
14.

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.

15.

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M.

Cancer. 2006 May 15;106(10):2218-23.

16.

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.

Biernat W, Debiec-Rychter M, Liberski PP.

Pol J Pathol. 1998;49(4):267-71.

PMID:
10323080
17.

Clinical significance of molecular biomarkers in glioblastoma.

Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P.

Can J Neurol Sci. 2010 Sep;37(5):625-30.

PMID:
21059509
18.

Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.

Kastenhuber ER, Huse JT, Berman SH, Pedraza A, Zhang J, Suehara Y, Viale A, Cavatore M, Heguy A, Szerlip N, Ladanyi M, Brennan CW.

Acta Neuropathol. 2014 May;127(5):747-59. doi: 10.1007/s00401-013-1217-3. Epub 2013 Nov 29.

19.

New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.

Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, Gonzalez-Darder J, Quilis V, Monleon D, Celda B, Cerdá-Nicolas M.

Mod Pathol. 2010 Jun;23(6):856-65. doi: 10.1038/modpathol.2010.62. Epub 2010 Mar 19.

20.

Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.

Quaranta M, Divella R, Daniele A, Di Tardo S, Venneri MT, Lolli I, Troccoli G.

Tumori. 2007 May-Jun;93(3):275-80.

Supplemental Content

Support Center